Literature DB >> 15033145

Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients.

Alessandro Cicolin1, Leonardo Lopiano, Maurizio Zibetti, Elena Torre, Alessia Tavella, Giulia Guastamacchia, Anna Terreni, George Makrydakis, Elisa Fattori, Michele Maria Lanotte, Bruno Bergamasco, Roberto Mutani.   

Abstract

Patients affected by Parkinson's disease (PD) often complain of disturbed sleep resulting from nighttime motor disabilities such as nocturnal akinesia, tremor and rigidity, motor behaviour during REM sleep or periodic leg movements (PLM) during sleep. Sleep may also be affected by dopaminergic and anticholinergic drugs or coexisting depressive syndrome. Deep brain stimulation (DBS) of subthalamic nucleus (STN) effectively reduces PD motor disability. The aim of this study is to evaluate the sleep architecture modifications after STN DBS. We assessed five patients (two men and three women, mean age 63.8+/-3.3 years, with a mean history of PD of 13.8+/-4.9 years) who underwent STN DBS. The mean levodopa equivalent dosage (LED) was 1010+/-318 mg before surgery and 116+/-93 mg 3 months after surgery. Polysomnography (PSG) with audiovisual recordings was performed on two separate nights, the first assessment in the week before surgery and the second 3 months after surgery. Three months after surgery, PSG showed an increase in total sleep time, in the longest period of uninterrupted sleep, and in the percentage of stage 3-4 NREM sleep, while there was a reduction of wakefulness after sleep onset. PLM, apnea-hyopnea index and REM sleep behaviour disorder were unaffected by STN DBS. STN DBS seems to be an effective therapeutic option for the treatment of advanced Parkinson's disease because it improves the cardinal symptoms and also seems to improve sleep architecture.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15033145     DOI: 10.1016/j.sleep.2003.10.010

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  31 in total

1.  Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Michael Gara; Karina Bienfait; Allison Dicke; Cynthia L Comella; Charles Cantor; Lee Hyer
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

2.  Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?

Authors:  Rupam Borgohain; Rukmini Mridula Kandadai; Afshan Jabeen; Meena A Kannikannan
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

Review 3.  Pathophysiologic mechanisms in REM sleep behavior disorder.

Authors:  Mark W Mahowald; Carlos H Schenck; Michel A Cramer Bornemann
Journal:  Curr Neurol Neurosci Rep       Date:  2007-03       Impact factor: 5.081

4.  Sleep disorders and daytime sleepiness in Parkinson's disease.

Authors:  Renee Monderer; Michael Thorpy
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

Review 5.  [REM sleep behavior disorder as a prodromal stage of α-synucleinopathies: symptoms, epidemiology, pathophysiology, diagnosis and therapy].

Authors:  W H Oertel; C Depboylu; M Krenzer; D Vadasz; V Ries; F Sixel-Döring; G Mayer
Journal:  Nervenarzt       Date:  2014-01       Impact factor: 1.214

Review 6.  Deep brain stimulation for Parkinson's disease.

Authors:  Patricia Limousin; Irene Martinez-Torres
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 7.  Sleep disturbances in Parkinson's disease.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Karina Bienfait
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

Review 8.  Circadian and sleep disorders in Parkinson's disease.

Authors:  Aleksandar Videnovic; Diego Golombek
Journal:  Exp Neurol       Date:  2012-08-23       Impact factor: 5.330

9.  Sleep dysfunction and its management in Parkinson's disease.

Authors:  Scott J Kutscher; Siavash Farshidpanah; Daniel O Claassen
Journal:  Curr Treat Options Neurol       Date:  2014-08       Impact factor: 3.598

Review 10.  Parasomnias: an updated review.

Authors:  Michael J Howell
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.